KR890003387A - 국소활성을 갖는 이중-가닥 RMAs조성물 - Google Patents

국소활성을 갖는 이중-가닥 RMAs조성물 Download PDF

Info

Publication number
KR890003387A
KR890003387A KR1019880010300A KR880010300A KR890003387A KR 890003387 A KR890003387 A KR 890003387A KR 1019880010300 A KR1019880010300 A KR 1019880010300A KR 880010300 A KR880010300 A KR 880010300A KR 890003387 A KR890003387 A KR 890003387A
Authority
KR
South Korea
Prior art keywords
dsrna
mismatched
topical
pharmaceutical composition
surfactant
Prior art date
Application number
KR1019880010300A
Other languages
English (en)
Other versions
KR970007904B1 (ko
Inventor
에이.카터 윌리암
Original Assignee
원본미기재
헴 리서어취 인코오포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 헴 리서어취 인코오포레이티드 filed Critical 원본미기재
Publication of KR890003387A publication Critical patent/KR890003387A/ko
Application granted granted Critical
Publication of KR970007904B1 publication Critical patent/KR970007904B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Details Or Accessories Of Spraying Plant Or Apparatus (AREA)
  • Credit Cards Or The Like (AREA)
  • Holo Graphy (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Abstract

내용 없음

Description

국소활성을 갖는 이중-가닥 RMAs조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 dsRMA자체의 표면이 전체적으로 음전하를 띄는 잘못 짝지워진 dsRNA만의 2개의 RNA가닥들의 2원 복합체를 나타낸다. 제2도는 음전하를 띈 dsRNA의 표면 가까이에 위치하는 양이온계 표면활성제 입자들에 양전하를 띈 부분 및 dsRNA 자체로부터 멀리 떨어진 표면에 존해하는 비-극성잔기들을 갖는 본 발명에 따른 잘못 짝지워진 dsRNA 3원 복합체(양이온계 표면활성제로 둘러싸인 2개의 상보적이기는 하나 잘못 짝지워진 RNA가닥)를 나타낸다.

Claims (10)

  1. 약학적으로 허용되는 국소담체 및 유효량의 잘못 짝지워진 dsRNA를 표면활성제와 더불어 2개의 잘못 짝지워진 dsRNA가닥들의 3원 복합체 형태로 함유하는 잘못 짝지워진 dsRNA로 치료하기가 쉬운/유효한 중상을 치료하기 위한 국소투여 약학조서물.
  2. 제2항에 있어서, 3원 복합체가 잘못 짝지워진 dsRNA가 표면활성제로 둘러싸인 마이셀 형태인 국소투여 약학조성물.
  3. 살정자 유효량의 살정자제 및 조성물의 총 중량을 기준으로 계산하여 0.001-10%의 잘못 짝지워진 dsRNA를 약학적으로 허용되는 담체내에 함유하는 살정자 및 항 비루스-활성을 갖는 국소 약학조성물.
  4. 제3항에 있어서, 인체 성뇨관을 자극하지 않는 윤활제를 또한 함유하는 살정자 및 항 비루스-활성을 갖는 국소 약학조성물.
  5. 제3항 도는 제4의 약학조성물로 피복된 콘돔.
  6. 비루스-감염된 피부, 눈 또는 점막조직에 잘못 짝지워진 dsRNA의 2개의 잘못 짝지워진 RNA가닥들이 표면활성제와 더불어 3원 복합제를 형성하는 안정화된 국소 약학조성물중의 치료학적 유효량의 잘못 짝지워진 dsRNA를 국소 투여함으로써 잘못 짝지워진 dsRNA로 치료하기 쉬운 피부, 눈 및 점막조직의 비루스 감염 치료방법.
  7. 제1항에 있어서, dsRNA의 양이 전체 조성물의 약 0.001-10중량%이고, 및 표면활성제의 양이 상기 전체 조성물의 0.005-20중량%인 국소투여 약학조성물.
  8. 제1항에 있어서, 잘못 짝지워진 dsRNA가 1/5-30 우라실 또는 구아니딘 염기를 함유하는 폴리이노시네이트 및 폴리시티 딜레이트의 복합체인 국소투여 약학조성물.
  9. 제1항에 있어서, dsRNA가 결합 절단 부위를 함유하며 및 dsRNA가 rIn.r(C11-14'U)n의 바람직한 치료율 특성을 나타내는 국소투여 약학조성물.
  10. 제11항에 있어서, dsRNA가 rIn.r(C11-14'U)n인 국소투여 약학조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880010300A 1987-08-12 1988-08-12 국소활성을 갖는 이중-쇄 RNAs 조성물 KR970007904B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8422687A 1987-08-12 1987-08-12
US07/084,226 1987-08-12
US084226 1987-08-12

Publications (2)

Publication Number Publication Date
KR890003387A true KR890003387A (ko) 1989-04-14
KR970007904B1 KR970007904B1 (ko) 1997-05-17

Family

ID=22183613

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880010300A KR970007904B1 (ko) 1987-08-12 1988-08-12 국소활성을 갖는 이중-쇄 RNAs 조성물

Country Status (20)

Country Link
EP (1) EP0303516B1 (ko)
JP (1) JP2714021B2 (ko)
KR (1) KR970007904B1 (ko)
CN (1) CN1031325A (ko)
AT (1) ATE108066T1 (ko)
AU (3) AU2053688A (ko)
CA (1) CA1327001C (ko)
DE (1) DE3850535T2 (ko)
DK (1) DK449988A (ko)
FI (1) FI883734A (ko)
HU (1) HU209749B (ko)
IE (1) IE66830B1 (ko)
IL (1) IL87415A (ko)
MX (1) MX12643A (ko)
NO (1) NO883564L (ko)
NZ (1) NZ225755A (ko)
PH (1) PH31174A (ko)
PT (1) PT88248B (ko)
RU (1) RU2061470C1 (ko)
ZA (1) ZA885874B (ko)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963532A (en) * 1987-11-25 1990-10-16 Hem Research, Inc. dsRNA-based prevention of viral escape
JPH04507083A (ja) * 1989-05-19 1992-12-10 ヘム・リサーチ・インコーポレーテッド 規定された構造の短い治療用ｄｓＲＮＡ
EP0695186A1 (en) * 1993-04-28 1996-02-07 Ribozyme Pharmaceuticals, Inc. Ocular delivery of nucleic acid
JP2690276B2 (ja) * 1995-01-10 1997-12-10 科学技術振興事業団 静電結合型高分子ミセル薬物担体とその薬剤
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
NZ547283A (en) 1998-03-20 2008-06-30 Commw Scient Ind Res Org Control of gene expression
EP1147204A1 (en) 1999-01-28 2001-10-24 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
AU2001249622B2 (en) 2000-03-30 2007-06-07 Massachusetts Institute Of Technology RNA sequence-specific mediators of RNA interference
WO2002044321A2 (en) 2000-12-01 2002-06-06 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Rna interference mediating small rna molecules
EP1229134A3 (en) 2001-01-31 2004-01-28 Nucleonics, Inc Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
JP2005324511A (ja) * 2004-05-17 2005-11-24 Kawamura Sangyo Kk 積層体及びその製造方法
UA93354C2 (ru) * 2004-07-09 2011-02-10 Гилиад Сайенсиз, Инк. Местный противовирусный препарат
US20060153844A1 (en) * 2004-12-29 2006-07-13 Thomas Kundig Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
US9139850B2 (en) 2005-05-19 2015-09-22 L'oreal Vectorization of dsRNA by cationic particles and topical use
FR2885808B1 (fr) * 2005-05-19 2007-07-06 Oreal Vectorisation de dsrna par des particules cationiques et utilisation topique.
WO2007102608A1 (ja) * 2006-03-06 2007-09-13 Nanocarrier Co., Ltd. 疎水性化合物の安定化剤
ES2588183T3 (es) * 2009-03-31 2016-10-31 Japan As Represented By Director-General Of National Institute Of Infectious Diseases Procedimiento para la prevención de la gripe utilizando una vacuna para administración intranasal
CN105434341B (zh) * 2015-12-22 2018-07-10 肇庆大华农生物药品有限公司 一种兽用聚腺尿苷酸注射液及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3582468A (en) * 1968-09-27 1971-06-01 Merck & Co Inc Recovery of double-stranded ribonucleic acid
BE793157A (fr) * 1971-12-21 1973-06-21 Beecham Group Ltd Substance antivirale
US4024222A (en) * 1973-10-30 1977-05-17 The Johns Hopkins University Nucleic acid complexes
US4415548A (en) * 1980-02-12 1983-11-15 Schmid Laboratories, Inc. Spermicidally lubricated prophylactics and method for making same
JPS57209050A (en) * 1981-06-19 1982-12-22 Jekusu Kk Condome
US4507281A (en) * 1981-10-13 1985-03-26 Exovir, Inc. Interferon-containing compositions
JPS59124514U (ja) * 1983-02-10 1984-08-22 不二ラテックス株式会社 避妊効果を確実に向上させたコンド−ム
FR2556727B1 (fr) * 1983-12-19 1990-01-19 Biostabilex Labo Pharma Nouvelles compositions therapeutiques a base d'adn a haut poids moleculaire et leur procede de preparation
CA1326450C (en) * 1985-08-26 1994-01-25 William A. Carter Modulation of aids virus-related events by double stranded rnas (dsrnas)

Also Published As

Publication number Publication date
IL87415A0 (en) 1989-01-31
JP2714021B2 (ja) 1998-02-16
PH31174A (en) 1998-03-20
DE3850535D1 (de) 1994-08-11
DK449988D0 (da) 1988-08-11
RU2061470C1 (ru) 1996-06-10
EP0303516A3 (en) 1989-12-06
ATE108066T1 (de) 1994-07-15
JPH01139531A (ja) 1989-06-01
FI883734A (fi) 1989-02-13
HUT47855A (en) 1989-04-28
NO883564L (no) 1989-02-13
AU1736592A (en) 1992-07-30
PT88248A (pt) 1989-06-30
EP0303516A2 (en) 1989-02-15
IL87415A (en) 1993-05-13
IE66830B1 (en) 1996-02-07
AU2053688A (en) 1989-04-20
HU209749B (en) 1994-10-28
NO883564D0 (no) 1988-08-11
NZ225755A (en) 1990-03-27
DE3850535T2 (de) 1995-01-12
KR970007904B1 (ko) 1997-05-17
MX12643A (es) 1993-09-01
CA1327001C (en) 1994-02-15
EP0303516B1 (en) 1994-07-06
AU1001395A (en) 1995-03-09
DK449988A (da) 1989-02-13
FI883734A0 (fi) 1988-08-11
ZA885874B (en) 1989-04-26
PT88248B (pt) 1995-03-01
IE882398L (en) 1989-02-12
CN1031325A (zh) 1989-03-01

Similar Documents

Publication Publication Date Title
KR890003387A (ko) 국소활성을 갖는 이중-가닥 RMAs조성물
BR9810745A (pt) Derivados de benzimidazol
BR0312286A (pt) pró-medicamentos de 2' e 3' - nucleosìdeo modificado para tratamento de infecções por flaviviridae
BR9813373A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente
BR9913157A (pt) Processos para tratar ou previnir infecção causada por pelo menos um vìrus das flaviviridae e doenças associadas com a referida infecção e infecção causada por pelo menos um vìrus do gênero hepacivìrus da flaviviridade e doenças associadas com a referida infecção, composição farmacêutica para tratar ou previnir infecções virais, e, composto
BR9811121A (pt) Produto, composição farmacêutica, e uso de um produto
KR960700742A (ko) 아토피성질환 치료약(atopic disease remedy)
BR9707325A (pt) Processo para o tratamento de um paciente afetado com uma doença mediada por il-1, composição farmacéutica e uso da mesma
YU7296A (sh) Farmaceutska kompozicija koja sadrži kombinaciju jedne protivvirusne supstance i jednog protivzapaljenskog glukokortikoida
BR0109336A (pt) Medicamento para a prevenção, melhora e/ou tratamento de uma complicação diabética, droga medicinal adequada ou utilizável como o mesmo, método para prevenir, melhorar e/ou tratar a complicação diabética, e a neuropatia, e, usos de um agente redutor do açúcar no sangue pós-prandial e pelo menos um agente selecionado de um agente anti-hipertensivo, um agente vasodilatador e um agente anti-hiperlipidêmico
MY117892A (en) Therapeutic compounds
ZA919317B (en) Novel hydroxamic acid and N-hydroxyurea derivatives and their use.
AU1865100A (en) Hyaluronate lyase used for promoting penetration in topical agents
ES2187845T3 (es) Solucion oftalmica vehiculo.
BR9805318A (pt) Método para tratamento de infecções dos olhos com azitromicina.
BR9914128A (pt) Composições antibióticas para tratamento do olho, ouvido e nariz
BR9910071A (pt) Composição farmacêutica, processos para aumentar e manter a homogeneidade de uma composição farmacêutica e para tratar, reverter, reduzir ou inibir infecções retrovirais, uso de abacavir, lamivudina, zidovudina ou de um derivado farmaceuticamente aceitável dos mesmos, e de um agente de deslizamento farmaceuticamente aceitável, artigo de manufatura, e, processo para a preparação de uma composição farmacêutica
CA2216569A1 (fr) Utilisation de derives d'oxazolidinone comme agents anti-penetrants dans une composition cosmetique et/ou dermatologique
ATE245975T1 (de) Adamantanaminenderivate zur bekämpfung von viren der familie bornaviridae
KR950016760A (ko) 치질 치료제
MX9805441A (es) Compuestos terapeuticos.
DK0410749T3 (da) Anthocyanidiner til behandling af ophthalmiske sygdomme
BR9712614A (pt) Composição farmacêutica,processos para aumentar e manter a homogeneidade de uma composição farmac&eutica,para tratar,reverter,reduzir ou inibir infeccões retrovirais e para preparação de uma composição farmacêutica,uso de lamivudina ou de um derivado farmaceuticamenete aceitável da mesma,de zidovudina,ou de um derivado farmaceuticamente aceitável da mesma e de um agente de deslizamento farmaceuticamente aceitável,e, artigo de amnufatura.
CA2465062A1 (en) Preventive and/or therapeutic agent for viral infection
US5993841A (en) Pharmaceutical composition and methods for using it

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20020821

Year of fee payment: 6

LAPS Lapse due to unpaid annual fee